Search

Displaying results 5391 - 5400 of 6949 in total
  1. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib is intended for the treatment of hematologic malignancies and the solid tumors. … Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels

    Categories: Receptor Protein-Tyrosine Kinases, antagonists & inhibitors
  2. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  3. Drug

    ODN M362

    go.drugbank.com/drugs/DB16485
    Experimental

    Categories: Experimental Unapproved Treatments for COVID-19
  4. Drug

    Fumaric acid

    go.drugbank.com/drugs/DB01677
    Investigational

    Categories: Antipsoriatics for Topical Use
  5. Drug

    CYNK-001

    go.drugbank.com/drugs/DB15722
    Investigational

    CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

  6. Drug

    Thymectacin

    go.drugbank.com/drugs/DB05116
    Investigational

    Thymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer.

  7. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis

  8. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia.

  9. Drug

    JB991

    go.drugbank.com/drugs/DB05081
    Experimental

    JB991 is a cyclopentenone prostaglandin analogue intended for treatment of psoriasis.

  10. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    Blonanserin is an atypical antipsychotic approved in Japan in January, 2008. It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. As a second-generation (atypical) ...

    Categories: Dopamine D2 Receptor Antagonists, Serotonin Receptor Antagonists